Larry Biegelsen has given his Buy rating due to a combination of factors reflecting the growth and potential of Bausch + Lomb Corporation’s products. His analysis indicates that Miebo, ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch + Lomb was put up for sale after a planned separation ... from sales of contact lenses and dry eye drugs Xiidra and Miebo. The company also sells surgical equipment to ophthalmologists.

Edward Bausch transformed the world of optics with groundbreaking inventions like the iris diaphragm shutter and advanced ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Bausch + Lomb's product portfolio includes several key offerings that contribute to its market position. The company's dry eye disease (DED) prescription drugs, particularly Miebo and Xiidra ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Bausch + Lomb's product portfolio includes several key offerings that contribute to its market position. The company's dry eye disease (DED) prescription drugs, particularly Miebo and Xiidra, have ...